Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial

NCT03868293 · View on ClinicalTrials.gov ↗

Study Summary

The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

Conditions Studied

Interventions

  • DEVICE Focused ultrasound

Study Locations (1)

Massachusetts

  • Brigham and women's Hospital — Boston

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-02-07
Est. Completion 2026-03-09
Phase NA

Sponsor

Brigham and Women's Hospital

929 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03868293

The ClinicalTrials.gov registry entry for NCT03868293 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 929 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Drug Resistant Epilepsy appearing as the primary indexed condition, and to 1 intervention — of which Focused ultrasound is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03868293 reports 1 study location spanning 1 distinct geographic area — top geographies include Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03868293 about?

NCT03868293 is a clinical study titled "Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial". The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

What is the current status of trial NCT03868293?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2019-02-07. Estimated completion is 2026-03-09.

What conditions does trial NCT03868293 study?

This clinical trial studies the following conditions: Drug Resistant Epilepsy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03868293?

The interventions under investigation include: Focused ultrasound (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03868293?

This trial is sponsored by Brigham and Women's Hospital, which has 929 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03868293 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial